This is a study designed to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of WEF-001 as monotherapy in patients with Advanced KRAS-mutant solid tumours.

Inclusion Criteria:

• Advanced KRAS-mutant solid tumor: pancreatic ductal adenocarcinoma, colorectal cancer, non small cell lung cancer, platinum-resistant serous ovarian cancer, cholangiocarcinoma or urothelial bladder cancer
• Progressive disease following at least one line of standard of care therapy
• Measurable disease as defined by RECIST v1.1
• ECOG ≤ 1

Exclusion Criteria:

• Active systemic infection requiring anti-infective therapy within 28 days prior to first dose of IMP
• Active cardiovascular disease
• Having a second active primary malignancy, requiring systemic administration of any cancer-related therapy
• Liver dysfunction
• Untreated brain metastasis and/or unstable neurological dysfunction
• Inflammatory bowel disease
• Active and untreated hyperthyroidism
• Lupus erythematosus within past 5 years